Related Experiment Video
Updated: May 6, 2026

Real Time In Vivo Tracking of Thymocytes in the Anterior Chamber of the Eye by Laser Scanning Microscopy
Published on: October 2, 2018
Transformation of Thyroid Eye Disease Phenotype Following Teprotumumab Treatment
Julie M Shabto1, Shanlee Stevens, Celestine Gregerson
1Department of Ophthalmology, Irving Medical Center, Edward S. Harkness Eye Institute, Columbia University, New York City, New York, U.S.A.
Abstract:
The authors report a case of a phenotypic shift of thyroid eye disease following treatment with teprotumumab. A 35-year-old female nonsmoker with Graves disease developed mild type I thyroid eye disease featuring unilateral lid retraction and was treated with teprotumumab. Following completion of treatment, a reactivation was associated with progression to severe type II phenotype, with marked extraocular muscle enlargement, bilateral proptosis, and nonsteroid-responsive compressive optic neuropathy requiring orbital decompression. This case raises important questions regarding the potential influence of Insulin-like growth factor 1 (IGF-1) suppression on the phenotype of thyroid eye disease.
More Related Videos
Related Concept Videos
Hyperthyroidism II: Pathophysiology
Graves Disease II: Pathophysiology

